May 15, 2020 / 6:45 AM / 18 days ago

BRIEF-Cantargia AB - Cantargia Presents New Preclinical Data

May 15 (Reuters) - Cantargia AB:

* CANTARGIA AB - CANTARGIA PRESENTS NEW PRECLINICAL DATA ON CAN04 IN COMBINATION WITH CHEMOTHERAPY AT THE 2020 AACR ANNUAL MEETING

* CANTARGIA AB - ANTIBODY CAN04 BINDS IL1RAP WITH HIGH AFFINITY AND FUNCTIONS THROUGH BOTH ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) AND BLOCKADE OF INTERLEUKIN-1 SIGNALING

* CANTARGIA AB - RESULTS SHOW SYNERGISTIC/ADDITIVE EFFECTS OF COMBINING CAN04 WITH THREE DIFFERENT REGISTERED PLATINUM-BASED THERAPIES

* CANTARGIA AB - A PHASE I TRIAL INVESTIGATING CAN04 IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR IS PLANNED TO START DURING 2020.

* CANTARGIA AB - NEW DATA IS PRESENTED SHOWING POTENT EFFECTS OF CAN04 WITH CISPLATIN ON TUMOR GROWTH IN A NOVEL ZEBRAFISH XENOGRAFT SCREENING SYSTEM FOR ANTI-CANCER DRUGS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below